A Registry to Evaluate the Direct Flow Medical Transcatheter Aortic Valve System (DISCOVER)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01845285 |
Recruitment Status : Unknown
Verified February 2016 by Direct Flow Medical, Inc..
Recruitment status was: Recruiting
First Posted : May 3, 2013
Last Update Posted : February 24, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this postmarket Registry is to assess the standard of care and clinical outcomes of the Direct Flow Medical Transcatheter Aortic Valve System used in clinical routine according to the approved commercial indications. Procedures and assessments required by this registry are generally considered standard of care for Transcatheter Aortic Valve Replacement patients.
Evaluation criteria will be the incidence of mortality/morbidity and adverse events clinical performance, and hemodynamic performance of the DEVICE via ultrasound (echo) and angiographic imaging.
Condition or disease | Intervention/treatment |
---|---|
Aortic Valve Stenosis | Device: Aortic Valve Replacement |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 1000 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 3 Years |
Official Title: | A Registry to Evaluate the Direct Flow Medical Transcatheter Aortic Valve System for the Treatment of Patients With Severe Aortic Stenosis |
Study Start Date : | March 2013 |
Estimated Primary Completion Date : | December 2016 |
Estimated Study Completion Date : | December 2019 |
Group/Cohort | Intervention/treatment |
---|---|
aortic valve disease
aortic valve replacement
|
Device: Aortic Valve Replacement
Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
Other Names:
|
- Freedom from all-cause mortality at 30 days [ Time Frame: 30 days ]
- Device Success (VARC defined) [ Time Frame: 30 days ]
- Absence of procedural mortality AND
- Correct positioning of a single prosthetic heart valve into the proper anatomic location AND
- Intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20mmHg or peak velocity <3m/s, AND no moderate or severe prosthetic valve regurgitation)
- Early Safety [ Time Frame: 30 days ]
- All-cause mortality
- All stroke (disabling and non-disabling)
- Life-threatening bleeding
- Acute Kidney Injury - Stage 2 or 3 (including renal replacement therapy)
- Coronary artery obstruction requiring intervention
- Major vascular complications
- Valve-related dysfunction requiring repeat procedure (BAV, TAVR, or SAVR)
- Clinical efficacy [ Time Frame: 30 days through 5 years ]
- All-cause mortality
- All stroke (disabling and non-disabling)
- Hospitalization for valve-related symptoms or worsening congestive heart failure
- Clinical efficacy [ Time Frame: 30 days through 5 years ]• NYHA Class III or IV
- Clinical efficacy [ Time Frame: 30 days through 5 years ]• Prosthetic heart valve dysfunction (mean aortic valve gradient ≥20mm Hg, EOA ≤0.9-1.1cm2 [depending on body surface area] and/or DVI <0.35, AND/OR moderate or severe prosthetic valve regurgitation)
- Time-related Valve Safety [ Time Frame: 5 years ]
• Structural valve deterioration:
- Valve-related dysfunction (mean aortic valve gradient (mean aortic valve gradient ≥20mmHg, EOA ≤0.9-1.1cm2 [depending on body surface area] and/or DVI <0.35, AND/OR moderate or severe prosthetic valve regurgitation)
- Requiring repeat procedure (TAVR or SAVR)
- Time-related Valve Safety [ Time Frame: 5 years ]
- Prosthetic valve endocarditis
- Prosthetic valve thrombosis
- Thromboembolic events (e.g., stroke)
- VARC bleeding, unless clearly unrelated to valve therapy (e.g., trauma)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 71 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Candidates for this study must meet all of the Indications criteria and none of the Contraindications.
Inclusion Criteria (Indications):
- Age > 70 years old
-
Severe aortic valve stenosis determined by echocardiogram and Doppler:
- mean gradient >40 mmHg or peak jet velocity >4.0 m/s
- aortic valve area ≤0.8 cm2 or aortic valve area index ≤0.5 cm2/m2
- Symptomatic aortic valve stenosis (angina, congestive heart failure, NYHA Functional Class ≥ II, or syncope).
- Patient is an extreme risk candidate for open surgical aortic valve repair such that the site Investigators (interventional cardiologist and cardiothoracic surgeon) agree that medical factors preclude operation, based on the conclusion that the probability of death or serious morbidity exceeds the probability of meaningful improvement due to the patient's co-morbidities (such as, but not limited to, severe COPD, porcelain aorta, previous thorax irradiation) or logistic EuroSCORE ≥ 20.
Exclusion Criteria (Contraindications):
The Direct Flow Medical device is contraindicated for post implant balloon valvuloplasty.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01845285
Contact: Christopher Naber, MD | +49201897 0 | c.naber@contilia.de | |
Contact: Mary Edwards | 7075760420 ext 462 | medwards@directflowmedical.com |
Germany | |
Elisabeth Krankenhaus | Recruiting |
Essen, Germany, 45138 | |
Contact: Christopher Naber, MD +492018970 c.naber@contilia.de | |
Contact: Elisabeth Blank, RN +49 201 8973218 e.blank@contilia.de | |
Principal Investigator: Christopher Naber, MD | |
Italy | |
Ospedale Niguarda Ca' Granda | Recruiting |
Milan, Italy, 20162 | |
Contact: Federico DeMarco, MD +390264442585 federico.demarco@gmail.com | |
Principal Investigator: Federico DeMarco, MD |
Principal Investigator: | Christopher Naber, MD | Elisabeth Krankenhaus Essen GmbH |
Responsible Party: | Direct Flow Medical, Inc. |
ClinicalTrials.gov Identifier: | NCT01845285 |
Other Study ID Numbers: |
RP 001 |
First Posted: | May 3, 2013 Key Record Dates |
Last Update Posted: | February 24, 2016 |
Last Verified: | February 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
transcatheter valve replacement aortic valve disease aortic stenosis Aortic regurgitation,catheter Effective orifice area |
Aortic Valve Stenosis Constriction, Pathologic Pathological Conditions, Anatomical Aortic Valve Disease |
Heart Valve Diseases Heart Diseases Cardiovascular Diseases Ventricular Outflow Obstruction |